Cargando…

The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease

The abnormal accumulation of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) containing phosphorylated tau proteins are the main histopathological feature of Alzheimer’s disease (AD). Synaptic damage and loss are earlier events than amyloid plaques and NFTs in AD progress and best correlate with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xiaomin, Qiu, Yanyan, Zhao, Chenhao, Zhou, Zheng, Bao, Junze, Qian, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422899/
https://www.ncbi.nlm.nih.gov/pubmed/34471085
http://dx.doi.org/10.12659/MSM.933084
_version_ 1783749364683898880
author Yin, Xiaomin
Qiu, Yanyan
Zhao, Chenhao
Zhou, Zheng
Bao, Junze
Qian, Wei
author_facet Yin, Xiaomin
Qiu, Yanyan
Zhao, Chenhao
Zhou, Zheng
Bao, Junze
Qian, Wei
author_sort Yin, Xiaomin
collection PubMed
description The abnormal accumulation of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) containing phosphorylated tau proteins are the main histopathological feature of Alzheimer’s disease (AD). Synaptic damage and loss are earlier events than amyloid plaques and NFTs in AD progress and best correlate with cognitive deficits in AD patients. Soluble oligomeric Aβ initiates the progression of AD and tau mediates the subsequent synaptic impairments at an early stage of AD. In this review we discuss how Aβ or/and tau causes synaptic dysfunction. Aβ oligomers gather at synapses and give rise to synaptic death in a variety of ways such as regulating receptors and receptor tyrosine kinases, unbalancing calcium homeostasis, and activating caspases and calcineurin. A large amount of hyperphosphorylated tau exists in the synapse of the AD brain. Aβ-triggered synaptic deficits are dependent on tau. Soluble, hyperphosphorylated tau is much more correlated to cognitive decline in AD patients. Tau-targeted therapies have received more attention because the treatments targeting Aβ failed in AD. Here, we also review the therapy strategies used to intervene in the very early stages of AD. Soluble hyperphosphorylated tau forms a complex with cell surface receptors, scaffold proteins, or intracellular signaling molecules to damage synaptic function. Therefore, therapeutic strategies targeting synaptic tau at the early stage of AD may ameliorating pathology in AD. This review aims to provide an update on the role of oligomeric Aβ and soluble hyperphosphorylated tau in the early pathogenesis of Alzheimer’s disease and to develop a new treatment strategy based on this.
format Online
Article
Text
id pubmed-8422899
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-84228992021-09-27 The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease Yin, Xiaomin Qiu, Yanyan Zhao, Chenhao Zhou, Zheng Bao, Junze Qian, Wei Med Sci Monit Review Articles The abnormal accumulation of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) containing phosphorylated tau proteins are the main histopathological feature of Alzheimer’s disease (AD). Synaptic damage and loss are earlier events than amyloid plaques and NFTs in AD progress and best correlate with cognitive deficits in AD patients. Soluble oligomeric Aβ initiates the progression of AD and tau mediates the subsequent synaptic impairments at an early stage of AD. In this review we discuss how Aβ or/and tau causes synaptic dysfunction. Aβ oligomers gather at synapses and give rise to synaptic death in a variety of ways such as regulating receptors and receptor tyrosine kinases, unbalancing calcium homeostasis, and activating caspases and calcineurin. A large amount of hyperphosphorylated tau exists in the synapse of the AD brain. Aβ-triggered synaptic deficits are dependent on tau. Soluble, hyperphosphorylated tau is much more correlated to cognitive decline in AD patients. Tau-targeted therapies have received more attention because the treatments targeting Aβ failed in AD. Here, we also review the therapy strategies used to intervene in the very early stages of AD. Soluble hyperphosphorylated tau forms a complex with cell surface receptors, scaffold proteins, or intracellular signaling molecules to damage synaptic function. Therefore, therapeutic strategies targeting synaptic tau at the early stage of AD may ameliorating pathology in AD. This review aims to provide an update on the role of oligomeric Aβ and soluble hyperphosphorylated tau in the early pathogenesis of Alzheimer’s disease and to develop a new treatment strategy based on this. International Scientific Literature, Inc. 2021-09-02 /pmc/articles/PMC8422899/ /pubmed/34471085 http://dx.doi.org/10.12659/MSM.933084 Text en © Med Sci Monit, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Review Articles
Yin, Xiaomin
Qiu, Yanyan
Zhao, Chenhao
Zhou, Zheng
Bao, Junze
Qian, Wei
The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
title The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
title_full The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
title_fullStr The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
title_full_unstemmed The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
title_short The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
title_sort role of amyloid-beta and tau in the early pathogenesis of alzheimer’s disease
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422899/
https://www.ncbi.nlm.nih.gov/pubmed/34471085
http://dx.doi.org/10.12659/MSM.933084
work_keys_str_mv AT yinxiaomin theroleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT qiuyanyan theroleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT zhaochenhao theroleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT zhouzheng theroleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT baojunze theroleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT qianwei theroleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT yinxiaomin roleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT qiuyanyan roleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT zhaochenhao roleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT zhouzheng roleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT baojunze roleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease
AT qianwei roleofamyloidbetaandtauintheearlypathogenesisofalzheimersdisease